The Rise of Allografts in Regenerative Dentistry

Since Sandrine Dupriez joined Geistlich France as General Manager in February 2023, she has brought a breath of fresh air to Geistlich France – along with a significant expansion of the product range: allografts. In this interview, she talks about the growing demand for allogeneic transplants, the strategic partnership with O.S.T Développement, and how working in different roles abroad has enriched her professional life.

Redefining the Regeneration Portfolio

What was your initial thought when you first heard about allografts?

When I started at Geistlich France just over two years ago, my team came straight to me and said, “We need allografts!” I immediately saw the huge potential. Today, just one year later, allogeneic grafts are an integral part of the portfolio and play a key role in shaping the strategic direction of Geistlich France.

How do you assess the current trends and challenges in the French market?

There’s a strong and growing demand for allografts in France, especially in reconstructive procedures. Our sales reps consistently heard from dentists asking: “When will you have allografts?” Some of our key opinion leaders even combine xenograft with allograft for complex bone augmentation procedures, using Geistlich Bio-Oss® with Allodyn®.

What role do the products in the Allodyn® Select line and complementary offerings such as Regenfast® and Pocket X® Gel play in your strategy?

These products support specific surgical needs, but adoption has been slower in France. Some dentists want more local case studies, which we’re working on. Younger, more innovative practitioners are more open to trying new solutions, and we’re focusing our efforts there.

Strategic Collaborations and Clinical Value

How do Allodyn® and Geistlich Bio-Oss® complement each other in the product portfolio?

Actually, they complement each other. Geistlich Bio-Oss® has long been our star product, but allografts like Allodyn® offer faster healing. By combining the two, we get the best of both worlds - speed from Allodyn® and density from Geistlich Bio-Oss®. This combination meets the evolving expectations of patients who want quicker results and gives us a more credible and diverse portfolio.

How did you structure your collaboration with O.S.T Développement and what successes have you achieved so far?

Reaching our objectives has been a major success. But beyond the numbers, the collaboration with the O.S.T. team has been truly fantastic. We have a great working relationship - very open and solution-oriented. Whenever a situation arises, even if it’s not yet a problem, we talk it through early. That kind of proactive communication makes all the difference. What makes it work so well is that our values align - trust, clinical evidence, innovation, and a strong sense of collaboration. These shared principles have made the partnership not only productive but also genuinely enjoyable.

How do you think the collaboration with O.S.T Développement supports Geistlich’s goal of being perceived as the world’s leading regeneration specialist?

It’s a crucial step. Without allografts, we wouldn’t be seen as serious players in regeneration. This partnership shows we’re listening to the market and evolving with it.

Leadership with a Global Outlook

How has your international experience and passion for discovering new cultures influenced your work at Geistlich France?

Having worked across continents, I’ve brought a blend of North American openness and European relationship-building to the team. In North America, management is more collaborative and less hierarchical - something I’ve integrated into our culture here. It’s helped create a more open, communicative environment where everyone feels valued and aligned towards shared goals. We share this mindset at the affiliate and the headquarter.

Please complete the sentence: Everyone should know about Geistlich that…

We are the leader in regenerative dentistry, committed to providing clinicians with the best solutions to deliver outstanding care to their patients.

*Product availability may vary by country or region. Please contact your local Geistlich Pharma representative for detailed information.